Category Archives: Regenerative Medicine

As many as 104 people who arrived in Tamil Nadu from various countries have tested Covid-19 positive till date, of whom 82 were detected with the S gene drop variant of coronavirus, state Minister Ma Subramanian said on Wednesday.

The samples of the 82 passengers have been sent to the Institute for Stem Cell Science and Regenerative Medicine (inStem), Bengaluru, for genomic sequencing analysis, the Minister for Medical and Family Welfare said.

All the 82 passengers are fine, he told reporters.

To a query, a health department official told PTI all the 104 passengers comprise of those arriving from at risk and non-risk countries to Tamil Nadu with effect from December 1.

On test samples already sent to inStem, Bengaluru last week, he said the department has received the results of 13 people who were tested, of which one was confirmed to have the Omicron variant of the coronavirus, the delta variant in eight and four non-sequence.

On December 15, Tamil Nadu declared its first Omicron variant of coronavirus, which was a 47 year-old passenger who arrived from Nigeria.

Meanwhile, to step up surveillance at international airports, the government has requested the Centre to allow the health department to conduct COVID-19 tests of all international passengers arriving to Tamil Nadu, as against the current practice of testing those arriving from at risk countries, the minister said.

On the vaccination front, he said the 16th state-wide mega vaccination camp would be held on December 26 (Sunday), targeting 93 lakh people who are eligible to receive the second dose of vaccination.

Earlier in the day, Subramanian declared open digital display boards at the Government Kilpauk Medical College premises, following the announcement made in the state assembly.

In the first phase, 25 government medical college hospitals would be equipped with such digital display boards, totally costing Rs 1.25 crore, which would inform patients about the services offered in the respective hospitals, he said.

The information displayed on the boards would be in Tamil and English, he said.

Original post:
104 international passengers have tested Covid-19 positive so far: TN Health Minister - The Indian Express

DUBLIN--(BUSINESS WIRE)--The "Global Regenerative Medicine Partnering Terms and Agreements 2014 to 2021" report has been added to ResearchAndMarkets.com's offering.

The Global Regenerative Medicine Partnering Terms and Agreements 2014-2021 report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.

The report takes the reader through a comprehensive review Regenerative Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Regenerative Medicine partnering deals.

The report presents financial deal term values for Regenerative Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Regenerative Medicine partnering field; both the leading deal values and most active Regenerative Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 1600 online deal records of actual Regenerative Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

A comprehensive series of appendices is provided organized by Regenerative Medicine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Regenerative Medicine partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Regenerative Medicine technologies and products.

Key Benefits

Global Regenerative Medicine Partnering Terms and Agreements 2014-2021 provides the reader with the following key benefits:

In Global Regenerative Medicine Partnering Terms and Agreements 2014-2021, the available deals are listed by:

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Regenerative Medicine dealmaking

2.1. Introduction

2.2. Regenerative Medicine partnering over the years

2.3. Most active Regenerative Medicine dealmakers

2.4. Regenerative Medicine partnering by deal type

2.5. Regenerative Medicine partnering by therapy area

2.6. Deal terms for Regenerative Medicine partnering

2.6.1 Regenerative Medicine partnering headline values

2.6.2 Regenerative Medicine deal upfront payments

2.6.3 Regenerative Medicine deal milestone payments

2.6.4 Regenerative Medicine royalty rates

Chapter 3 - Leading Regenerative Medicine deals

3.1. Introduction

3.2. Top Regenerative Medicine deals by value

Chapter 4 - Most active Regenerative Medicine dealmakers

4.1. Introduction

4.2. Most active Regenerative Medicine dealmakers

4.3. Most active Regenerative Medicine partnering company profiles

Chapter 5 - Regenerative Medicine contracts dealmaking directory

5.1. Introduction

5.2. Regenerative Medicine contracts dealmaking directory

Chapter 6 - Regenerative Medicine dealmaking by technology type

Chapter 7 - Partnering resource center

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

Appendices

Appendix 1 - Regenerative Medicine deals by company A-Z

Appendix 2 - Regenerative Medicine deals by stage of development

Appendix 3 - Regenerative Medicine deals by deal type

Appendix 4 - Regenerative Medicine deals by therapy area

Appendix 5 - Deal type definitions

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/j6f6e7

Read more from the original source:
Global Regenerative Medicine Partnering Report/Directory 2021: Terms and Agreements for 1600 Deals 2014-2021 - ResearchAndMarkets.com - Business Wire

DUBLIN--(BUSINESS WIRE)--The "Stem Cell/Cord Blood Banking Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

The global stem cell/cord blood banking market is expected to grow from $8.16 billion in 2020 to $8.61 billion in 2021 at a compound annual growth rate (CAGR) of 5.5%. The market is expected to reach $12.51 billion in 2025 at a CAGR of 9.8%.

Major players in the stem cell/cord blood banking market are AMAG Pharmaceuticals, Cordlife, Cryo-Cell International, Esperite, and Americord Registry LLC.

The stem cell/cord blood banking global market consists of sales of stem cell/cord blood banking services and related goods. Cord stem cells are referred to as regenerative medicines which help in regeneration of tissues or cells in the body. Stem cells therapy is designed to aid the physician in performing medical treatment of different types of cancers, neurodegenerative diseases, graft-versus-host disease and heart diseases.

The stem cell/cord blood banking market covered in this report is segmented by cell type into adult stem cells, umbilical cord blood stem cells, embryonic stem cells. It is also segmented by service into collection, processing, analysis, storage; by bank type into public, private and by application into leukemia, anemia, thalassemia, autism, cerebral palsy, diabetes, others.

Lack of awareness especially among pregnant women is a major restraint for the stem cell/cord blood banking market. This is mainly because a majority of pregnant women are unaware of the functioning of the public cord blood banks. Hence, this option is not fully explored despite the advantages of stem cell transplantation in treating cancer.

For example, according to the survey by International Journal of Reproduction, Contraception, Obstetrics and Gynecology (IJRCOG), only 45% of pregnant women were informed about the uses of umbilical cord blood during pregnancy, just 5% were aware about the cost of the procedure and less than 1% were aware about the availability of cord blood banking.

Pairing of cord blood and tissue storage with genetic testing services is an emerging trend in the stem cell/cord blood banking market. Such pairing is possible and efficient because of its complimentary services to the existing clients, thereby helping in expanding their product portfolio. For example, genetic testing company Natera launched the Evercord cord blood and tissue storage service that enables expectant parents to collect, store and potentially retrieve their newborn's cord blood and tissue for therapeutic use in transplantation and regenerative medicine applications.

Increasing number of cancer patients is a major driver for the stem cell /cord blood banking market. Cancer diseases such as leukemia and multiple myeloma can be treated by stem cell transplant. In stem cell transplant, treatment can be either done by autologous transplant in which the stem cells come from the same person who gets the transplant or by allogeneic transplant in which means the stem cells come from a matched related or unrelated donor.

The US Food and Drug Administration (FDA) outlines guidance related to stem cells/cord blood banking in accordance with section 212 of the Small Business Regulatory Enforcement Fairness Act (Public Law 104-121). As per this act, stem cells sourced from cord blood for unrelated allogeneic use are regulated by the FDA, and, in order to distribute these products, distributors need to get a license from the FDA.

These licenses are provided by the FDA after reviewing the manufacturing and the storage conditions. In this regard, the American Association of Blood Banks (AABB) and other regulatory agencies also work with the FDA. Hence, the regulatory scenario related to the stem cells/cord blood banking market is expected to keep a check on companies involved in this market.

Key Topics Covered:

1. Executive Summary

2. Stem Cell/Cord Blood Banking Market Characteristics

3. Stem Cell/Cord Blood Banking Market Trends and Strategies

4. Impact Of COVID-19 On Stem Cell/Cord Blood Banking

5. Stem Cell/Cord Blood Banking Market Size and Growth

5.1. Global Stem Cell/Cord Blood Banking Historic Market, 2015-2020, $ Billion

5.1.1. Drivers Of the Market

5.1.2. Restraints On the Market

5.2. Global Stem Cell/Cord Blood Banking Forecast Market, 2020-2025F, 2030F, $ Billion

5.2.1. Drivers Of the Market

5.2.2. Restraints On the Market

6. Stem Cell/Cord Blood Banking Market Segmentation

6.1. Global Stem Cell/Cord Blood Banking Market, Segmentation by Cell Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

6.2. Global Stem Cell/Cord Blood Banking Market, Segmentation by Service, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

6.3. Global Stem Cell/Cord Blood Banking Market, Segmentation by Bank Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

6.4. Global Stem Cell/Cord Blood Banking Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

7. Stem Cell/Cord Blood Banking Market Regional and Country Analysis

7.1. Global Stem Cell/Cord Blood Banking Market, Split by Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

7.2. Global Stem Cell/Cord Blood Banking Market, Split by Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/587yea

Visit link:
Stem Cell/Cord Blood Banking Global Market Report 2021: COVID-19 Impact Analysis, Growth and Forecasts to 2030 - ResearchAndMarkets.com - Business...

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a persons innate regenerative potential to restore function, today shared the results from its FX-322-113 study, a placebo-controlled trial evaluating the administration of FX-322 in subjects with severe sensorineural hearing loss (SNHL). In the study, FX-322 was associated with a hearing signal as shown by improvements by four subjects in a sentence-in-noise test.

FX-322-113 is a double-blind, placebo-controlled Phase 1b study designed to assess the local and systemic safety of a single dose of FX-322, and to evaluate hearing responses in a cohort of individuals with severe SNHL (pure tone average deficit between 71-90 decibel (dB) hearing level), a patient population that may have considerable damage to their inner ears and where cochlear implants may be the only potential intervention to improve hearing. Subjects were randomized 4:1 and received either FX-322 or placebo in one ear. Safety, otologic and audiologic assessments were conducted at days 30 and 90 following administration of FX-322 or placebo.

To gain a more comprehensive understanding of the potential impact of FX-322 in this population, the Company evaluated hearing function using multiple tests of speech perception in both quiet and noisy backgrounds, including the Bamford-Kowal-Bench Sentence-in-Noise exam (BKB-SIN). BKB-SIN is a validated test designed for severe SNHL populations (including cochlear implant patients), measuring the change in signal-to-noise ratios (SNR) required for a subject to correctly repeat words in a sentence.

In the FX-322-113 study, BKB-SIN test improvements were observed in four subjects, all of whom exceeded the 95 percent critical difference of 3.1 dB SNR, with two subjects showing a 6 dB response. A single placebo patient had a 3.6 dB change. In the study, subjects did not show substantial changes in speech perception measures in quiet, the safety profile in the study was favorable and there were no treatment-related serious adverse events reported.

Given the level of cochlear damage, identifying single words in any audiologic test can be very challenging for these individuals. Response to the BKB-SIN test and a 6 dB improvement in the signal-to-noise ratio in multiple severe subjects is highly encouraging and consistent with the improvement we see in some patients following cochlear implantation, said Ren Gifford, Ph.D., Professor and Director, Cochlear Implant Research Laboratory Department of Hearing and Speech Science at Vanderbilt University and a member of Frequencys clinical advisory board. This is the real-world equivalent to being able to halve the distance between two people in a conversation, which can be very impactful on an individuals ability to communicate and engage in society. It is exciting to consider the potential of a restorative therapeutic as a component of the treatment paradigm for individuals with severe SNHL, either as a stand-alone treatment or in combination with hearing technology such as hearing aids and cochlear implants, to improve patient outcomes.

Brian Monson, Ph.D., an assistant professor in the Department of Speech and Hearing Science in the College of Applied Health Science at the University of Illinois added: Based on data pointing to FX-322 being localized in the higher frequency portion of the cochlea, as well as the proposed mechanism of action, these promising results are suggestive both of a hearing signal and potential functional improvements enabling speech perception in a noisy environment. These study findings are important as this outcome cannot currently be achieved using hearing devices that amplify sound, further highlighting the potential for a restorative intervention to enhance speech clarity.

FX-322 is Frequencys lead hearing restoration product candidate and is designed to regenerate auditory hair cells to restore hearing function. Frequency currently is enrolling a new Phase 2b (FX-322-208) study of subjects with noise-induced or sudden sensorineural hearing loss, with hearing loss severities primarily in the moderate to moderately severe ranges (35 85 dB).

This is the third FX-322 study where we have observed a hearing signal, furthering our confidence in our clinical program and the potential of a regenerative treatment for sensorineural hearing loss. The learnings from this study, and all of our early-phase studies to date, have provided Frequency and the field overall with important insights as we extend our understanding of how our therapeutic candidate may provide clinically meaningful benefit to the millions of individuals with SNHL that today have no restorative treatment options, said David L. Lucchino, Frequencys Chief Executive Officer.

About Frequency Therapeutics

Frequency Therapeutics is leading a new category in regenerative medicine that aims to restore function first in hearing loss and then in multiple sclerosis (MS) by developing therapeutics that activate a persons innate regenerative potential within the body through the activation of progenitor cells to restore lost function. Frequencys hearing research focuses on cochlear restoration and auditory repair, and its lead asset, FX-322, is a small-molecule product candidate that is the first to show statistically significant and clinically meaningful hearing improvements in clinical trials for SNHL. Frequency is also following early restorative signals in MS to develop medicines with the same underlying regenerative science being brought to hearing loss.

Headquartered in Lexington, Mass., Frequency has an ex-U.S. license and collaboration agreement with Astellas Pharma Inc. for FX-322, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, the Scripps Research Institute and Cambridge Enterprises Limited. For more information, visit http://www.frequencytx.com and follow Frequency on Twitter @Frequencytx.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the interpretation and implication of the results and learnings of FX-322-113, the timing and design of the new Phase 2b trial of FX-322, including the type of SNHL that the enrolled patients will have, the treatment potential of FX-322, the ability of our technology platform to provide patient benefit, the ability to continue to develop our Progenitor Cell Activation (PCA) platform and identify additional product candidates, and the potential application of the PCA platform to other diseases, including MS.

These forward-looking statements are based on managements current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of COVID-19 on the Companys ongoing and planned clinical trials, research and development and manufacturing activities, the Companys business and financial markets; the Company has incurred and will continue to incur significant losses and is not and may never be profitable; the Companys need for additional funding to complete development and commercialization of any product candidate; the Companys dependence on the development of FX-322; the unproven approach of the PCA platform and the inability to identify additional potential product candidates; the lengthy, expensive and uncertain process of clinical drug development and regulatory approval; the Companys limited experience successfully obtaining marketing approval for and commercializing product candidates; the results of earlier clinical trials not being indicative of the results from later clinical trials; differences between preliminary or interim data and final data; adverse events or undesirable side effects; disruptions at the FDA and other regulatory agencies; failure to identify additional product candidates; new or changed legislation; failure to maintain Fast Track designation for FX-322 and such designation failing to result in faster development or regulatory review or approval; ability to seek and receive Breakthrough Therapy designation for FX-322; the Companys ability to enroll and retain patients in clinical trials; costly and damaging litigation, including related to product liability or intellectual property or brought by stockholders; dependence on Astellas Pharma Inc. for the development and commercialization of FX-322 outside of the United States; misconduct by employees or independent contractors; reliance on third parties, including to conduct clinical trials and manufacture product candidates; compliance with changing laws and regulations, including healthcare and environmental, health, data privacy and safety laws and regulations; failure to obtain, maintain and enforce protection of patents and other intellectual property rights covering product candidates; security breaches or failure to protect private personal information; attracting and retaining key personnel; and the Companys ability to manage growth.

These and other important factors discussed under the caption Risk Factors in the Companys Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 15, 2021 and its other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent managements estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Companys views as of any date subsequent to the date of this press release.

Read the original here:
Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise -...

LAWRENCE The human body contains trillions of cells at any given moment, each doing highly specialized work to help us function but they dont operate in isolation. Imagine a sophisticated FedEx or UPS delivery network empowering communication between our cells. The nano-sized delivery vehicles in this scenario are called exosomes, and a company born from technology developed at the University of Kansas is harnessing the power of these tiny vessels to enable tomorrows medical breakthroughs.

Clara Biotech, founded by KU engineering alumnus Jim West and former KU professor of chemical & petroleum engineering and chemistry Mei He, has spent the last three years refining a novel technology to isolate and purify exosomes, which can be used for early disease diagnosis, targeted drug delivery, cancer immunotherapy and other forms of regenerative medicine.

Now, the company is poised to commercialize its first product after recently finalizing $1.5 million in seed funding and being recognized in a national competition. Clara Biotech was the only Midwest company singled out in MedTech Innovators Biotools Innovator program, which recognizes the 10 best life science tools startups. The company received $10,000 for securing a spot in the 2021 cohort and a $5,000 best-video award for a one-minute spot introducing the company and detailing what sets it apart.

Clara Biotech was founded to help move exosomes from the bench to the bedside, said West, who serves as Claras CEO. Our company is about building a platform that everybody can leverage to bring their products to market and help solve challenges around isolation and purification, which today is one of the number one issues in the field.

Exosomes deliver genetic information to cells throughout the body. Exosomes from regenerative cells, such as stem cells, can help the body heal and repair itself. Exosomes released from diseased cells might be used for early detection and diagnosis of cancer and other conditions.

But at 100 nanometers in diameter less than the wavelength of visible light exosomes are difficult to handle.

Clara Biotechs patented ExoRelease platform is unique in the industry. Current processes rely on bulk isolation, whereas Claras capture and release technology isolates pure exosomes. This allows researchers to easily isolate and target specific exosomes including cardiac, neurological, cancer and others and use them for therapeutic treatments and drug delivery platforms.

Im very excited about the work that Clara Biotech is doing to improve exosome purification, said Kathryn Zavala, managing director of BioTools Innovator. Their technology has the potential to significantly impact how we diagnose and treat diseases by advancing the field of exosome research and development.

Clara Biotech launched in 2018 with a Small Business Innovation Research grant from the National Cancer Institute and received training through the National Science Foundations Innovation Corps (I-Corps) program on how to transfer knowledge into products and processes that benefit society. It has seven full-time employees, and its lab is housed in the KU Innovation Park.

Clara Biotech is an example of how KU innovation provides the foundation to form a company that addresses societal needs and creates Kansas jobs, said Tricia Bergman, KUs director of strategic partnerships. It also illustrates how technology developed in KU labs can transition into the KU Innovation Park, where the company can continue to develop through ongoing partnerships with the university.

Until now, Clara Biotech has provided lab services to its customers. Now, its moving toward packaging its technology so other companies, labs and researchers can leverage it to complete the isolation process themselves.

Were trying to democratize access to these exosomes, West said.

Clara Biotech is beta-testing kits containing its isolation technology with promising results from early adopters and hopes to launch its first product by the end of the year.

Building a company is probably the hardest thing Ive ever done in my life, but its also super rewarding, West said. The work were doing is really important.

Photo: Jim West, CEO of Clara Biotech, holds the two checks his company won at MedTech Innovators Biotools Innovator program in San Diego in October.

Go here to see the original:
Biotech company with KU roots wins national competition, secures funding to help move research 'from bench to bedside' | The University of Kansas - KU...

Thirteen passengers who arrived from at risk and non-risk countries to Tamil Nadu till date have tested Covid-19 positive and their RTPCR Samples have been sent to Bengaluru for genomic sequencing analysis, Tamil Nadu Minister Ma Subramanian said on Thursday.

The minister for health and family welfare said 9,012 people have so far arrived from at risk countries of which 11 have tested Covid-19 positive while 33,112 people arrived from non-risk countries, of which two have tested positive.

Of the 13, one has been asymptomatic and is under home isolation. Seven people are under treatment in King Institute of Preventive Medicine and Research, two in Annal Gandhi Memorial Hospital, Tiruchirappalli and one in Government Medical College Hospital, Nagercoil and two in private health care facilities, he told reporters.

He said all were doing well and their samples have been sent to The Institute for Stem Cell Science and Regenerative Medicine (inStem), Bengaluru for genomic sequencing analysis.

Earlier in the day, he inspected the ACTech block located in the Anna University campus in Chennai after a student tested Covid-19 positive on Wednesday.

The 763 students in the campus underwent RTPCR tests, nine of them have tested Covid-19 positive. They have been admitted to the Kings Institute of Preventive Medicine and Research. Their samples have been collected and are being sent for genomic sequencing, he said.

Subramanian said the department has issued instructions to the University that professors, staff, wardens and students should adopt social distancing while having food in the canteen.

See more here:
13 passengers who arrived from overseas test Covid positive: TN health minister - The Indian Express

Its been said that art imitates life, but a UConn School of Dental Medicine researcher and his team have expanded that reflection to include the observation, science imitates food or, in this case, at least, the research he has been conducting was inspired by a tasty dessert supplement common in most household refrigerators.

Ali Tamayol, associate professor, UConn Department of Biomedical Engineering, and his team, Dr. Azadeh Mostafavi and Dr. Mohamadmahdi Samandari, had been working on development of bio-inks for 3D printing of implantable scaffolds for regenerative medicine applications. The goal had been to improve tissue regeneration by implanting the scaffold into the tissue defects caused by trauma, surgical procedures and degenerative disease. The team was testing various compounds that might be used to form porous bio-inks, which could be bio-printed and placed in the injured area.

Typically, 3D bio-printed scaffolds are made from hydrogels. However, hydrogel pores are smaller than the size of a cell, limiting the rate of cellular regrowth.

When eating whipped cream or using shaving cream, Tamayol realized that these foams were easy to apply, formed complex shapes, and were highly porous, leading him to conclude that he could produce scaffolding materials that might function in a similar fashion. They started testing biological materials that could be turned into a foam and used to support vascularization, muscle regeneration and function recovery.

Agitating gelatin solutions using a mixer, the researchers created a microbubble-embedded foam that could be used as a colloidal bio-ink. The microbubbles increased the size of the pores in the bio-ink, and improved its printability compared to regular gelatin-based bio-inks.

Defects were created in mice using a punching tool, and the 3D printed foam scaffolds were placed in the area where the tissue had been removed. In initial tests, new blood vessels formed, and in subsequent testing, the bio-ink was placed in more challenging injury models where muscle had been volumetrically damaged. Within eight weeks, the team found that muscles had regenerated, and lost function had been restored.

We knew that the regenerative abilities of most scaffolding materials we tried was limited, and that we needed to find more efficient materials and enlarge the pores for successful regeneration, Tamayol says. Egg whites may not be the best building material, but proteins are extremely useful in this process. The scaffolds formed through foaming of a gelatin-based solution are highly porous and easy to manufacture. These scaffolds can be produced using stationary printers or be printed directly inside patients bodies by portable 3D bio-printers.

This foundational research, Tamayol adds, has put UConn on the radar for other researchers and labs studying similar interventions. He established a start-up company to continue testing and working on this strategy of clinical implementation for regeneration of defected tissues. Commercial production, he stresses, is likely three to four years away, and will follow significant testing and clinical trials. Currently, his team is working with Dr. Nassim Annabis lab at UCLA, and Dr. Indranil Sinhas lab at Brigham and Womens Hospital.

A paper Tamayol co-wrote with Samandari detailing their research has been accepted in the scientific journal Applied Physics Review, and another paper detailing additional trials is now in preparation.

Well move into testing the benefits of the foam for bone and skin regeneration, but are quite excited about the potential for these materials and the many possible ways they might eventually be used in patients suffering from tissue injuries, Tamayol reflects. Its funny to think that whipped cream on my breakfast waffles led to this discovery, but sometimes its the simple things around us that lead to great creative ideas.

Read more from the original source:
UConn Researcher Finds Inspiration in the Refrigerator - UConn Today - UConn Today

CAMBRIDGE, Mass., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS) today announced the appointment of Martina Molsbergen as Interim Chief Business Officer. Ms. Molsbergen will be responsible for managing the Companys current partnerships and joint ventures as well as exploring new business development opportunities.

We are thrilled to welcome Martina to the Pyxis team as interim chief business officer, said Lara Sullivan, M.D., Chief Executive Officer of Pyxis. Her proven track record of leading and executing successful corporate and business development strategies within both large and small companies has yielded over 450 deals to date. Martina will serve as a key member of our executive leadership team as we advance our development portfolio with the potential to significantly benefit the lives of patients battling difficult to treat cancers.

Ms. Molsbergen added, Joining Pyxis at this moment in time is monumental. As a newly public company with over $300 million raised in 2021, Pyxis is strongly positioned to advance its current pipeline into clinical trials and, at the same time, aims to unlock significant value from a robust business development strategy. I am excited to be leading these strategic initiatives and look forward to continuing to marry organic growth with strategic partnerships and collaborations as we advance our multi-asset multi-platform portfolio.

Ms. Molsbergen brings 30 years of business development, marketing and entrepreneurial experience in areas with cutting-edge tools, technologies and products, including biotherapeutics, immunotherapies and regenerative medicine. Prior to joining Pyxis, she was Chief Executive Officer of C14 Consulting Group, a premier provider of strategic business strategy, licensing and deal negotiation serving life sciences companies. Ms. Molsbergen has held senior leadership business development roles for several biotech companies. As Vice President of Business Development of Crucell Holland BV, she managed the companys joint venture with DSM Biologics. Earlier, as Vice President of Business Development of Biowa, Inc., she negotiated more than 15 deals valued at over $2.5 billion. Prior to Biowa, she served as Vice President of Business Development of Zetiq Technologies Ltd. and Vice President of Pharmaceutical Development Services & Business Development of Patheon Inc.

Ms. Molsbergen sits on the Board of Directors of Score Pharmaceuticals, a novel antibody platform technology start-up, and OCMS Bio, Inc., an antibody tool company, of Bio-Path Holdings, Inc., a publicly traded company focused on RNAi antisense drug development, and of Blue Sky Surgical, a non-profit charity that provides free surgeries in underserved areas of Haiti. In 2018, she launched her own public charity, The C14 Foundation, dedicated to serving the poorest of the poor by cultivating sustainable solutions for meeting the basic needs of food, water, good health and shelter. She holds a Bachelor of Science in Chemical Engineering from Drexel University.

About Pyxis Oncology, Inc.Pyxis Oncology, Inc. is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. Pyxis develops its product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since its launch in 2019, Pyxis has developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that it is developing as monotherapies and in combination with other therapies. To learn more about Pyxis visit http://www.pyxisoncology.com.

Forward-Looking StatementsThis press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements are often identified by the use of words such as anticipate, aim, believe, can, continue, could, estimate, expect, intend, likely, may, might, objective, ongoing, plan, potential, predict, project, should, to be, will, would, or the negative or plural of these words, or similar expressions or variations, although not all forward-looking statements contain these words.We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified herein, and those discussed in the section titled Risk Factors set forth in PartII,Item 1A. of the Company's most recent Quarterly Report on Form10-Q and in our other filings with the SEC.These risks are not exhaustive.New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. In addition, statements that we believe and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.

Contacts:Courtney DuganVice President, Head of Investor Relations and Communicationsir@pyxisoncology.com

Ashley RobinsonLifeSci Advisors, LLCarr@lifesciadvisors.com

Jason Braco, Ph.D.LifeSci Communicationsjbraco@lifescicomms.com

Here is the original post:
Pyxis Oncology Appoints Martina Molsbergen as Interim Chief Business OfficerIndustry veteran brings expertise in corporate strategy and business...

Awesome!! I have been going to the center ever since it first opened and it has been a Godsend. On this last appointment, it had been a few months in between treatments and I was in agony. I could barely walk, even with the aide of a walker. Each step was extremely painful. The day after Dr. Lai performed the procedure, I was 100% pain-free on my left side and I can't wait for him to do the procedure on my right side. This is the reason I have been a patient of their's for over 2 yrs & I will NEVER change doctors by choice. I thank God for them.

My visit was very thorough. PA Villarreal was very helpful in discussing my medications and the RXs that I needed. Maxine was also very helpful, kind and considerate and thorough. The front desk is always very helpful, cheerful and kind. Thank You!

Dr. Tisdall and his staff went above and beyond! The medical staff was extremely compassionate, reassuring, and very thorough! The procedure was extremely successful in relieving my extreme pain again. I could never thank this team enough! God Bless you all for the excellent service and treatment! I would highly recommend Dr. Tisdall and this clinic for anyone suffering with spine or joint pain!

Great experience with this fun, crazy staff at this location for the past 3 yrs. Zero Complaints! Thank you Maria B. and PA Thomas Ezpinoza.

Dr. Tisdall has truly given me my life back. I have been a patient of his for 6 years. He has always been compassionate and understanding and truly wants his patients to have the best quality of life possible. His PAs and staff are always professional and friendly. They are the best!

The staff was great and professional. Very excellent!

Dr. Bourgeois is absolutely wonderful! He really listens to you and has helped my pain a great deal. He has given me two injections in my lumbar spine and one in my SI joint. I'm feeling so much better!!! I would recommend Dr. Bourgeois to everyone! He is great!

IT WAS GREAT, THE STAFF AND DR'S ARE VERY KIND, HELPFUL AND CARING. THEY ARE UNDERSTANDING AND EXPLAIN EVERYTHING CLEARLY.

I loved this office. I come to the Schertz office and I could not ask for better service. They are so efficient and polite. I feel that they truly care abut my health and my time. I love all the staff and the Dr. is wonderful.

I have been a patient of Dr. Tisdall for almost a year now. I have significant spine issues and Dr. Tisdall and PA Villereal have both provided excellent managed care with injections and pain medicines.

At my first appointment I was told that my pain could be reduced or eliminated, when I had given up hope that I would ever find a solution! I received compassion & support throughout the whole process and was treated with respect and understanding.

Dr. Tisdall and PA Espinosa,I would like to commend you for your caring knowledgeable and courteous attentiveness to my pain needs. I feel that I have my life back and I just wanted you to know that. If somebody I know should ask me who I would recommend as pain specialists YOU will be the ones I mention.Sincerely,Mr Thomas Barbee

As usual my visit was great. The staff is always in professional polite mode, and have always made me feel as they are there for me. Although mine was not a new patient visit, it was a new problem visit. I've been having problems with osteoporosis and I discussed the problem with PA Michael Reed. He Suggested steroid injections which was done on my last visit. I'm happy to say that the pain and discomfort has decreased by more than 80%. I'm also happy to say that PA Reed has been a part of my health care team for some time now, and I wouldn't have it any other way. His demeanor is always kind, and his care always exceed my expectations. I have and will have no problem referring family and friends, as a matter of fact I referred my wife for care. Thank you guys for all you do, and thank you Michael Reed, PAC

Always a good experience when I visit, and always have my questions answered. This is unlike most doctors who have just dismissed my pain in the past. I highly recommend them!

Dr Tisdall is knowledgeable and understanding, and he takes his time to understand patients needs. I personally now see PA Kurt Lee and he is awesome. I wouldn't change a thing!

My brother has had back pain for about 7 years, he started seeing Dr. Tisdall and PA Reed, and he is finally feeling some pain relief. Hopefully, soon, he will no longer need meds.

Dr. Tisdall and his staff are by far the most caring group of individuals in pain management speciality. Dr. Tisdall and his staff always treat each patient individually, and are very sensitive to the patients well being and feeling stigmatized. I am so thankful I'm under his care!

Dr. Tisdall is an amazing Dr. He treats you with the utmost respect and truly listens to you. After 5yrs, with a different Pain Mgmt. Dr., with no results, Dr. Tisdall tried a different procedure that gave me relief. No more opioids needed. I can't thank him enough. PA Reed, is also wonderful.

More here:
Pain Management SA | Regenerative Medicine | Spine & Joint ...

MIAMI, Nov. 5, 2021 /PRNewswire/ --Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it has received confirmation from the Financial Industry Regulatory Agency ("FINRA") that the pending marketplace name change and trading symbol change request to Organicell Regenerative Medicine, Inc. and "OCEL" has been approved. Accordingly, effective Monday November 8, 2021, the company will have the marketplace name Organicell Regenerative Medicine, Inc. and Organicell common stock will begin trading under the symbol "OCEL" on the OTCPink tier of the over-the -counter market operated by OTC Markets Group, Inc.

No action is required to be taken by Organicell stockholders with respect to the name and symbol changes. Outstanding share certificates are not affected and do not need to be exchanged.

This approved corporate action was related to Company's previous amendment to its Articles of Incorporation on June 20, 2018, whereby the Company's corporate name had been changed to Organicell Regenerative Medicine, Inc., from Biotech Products, Services & Research Inc. However that name change and a corresponding trading symbol change was never effectuated in the marketplace by FINRA.

The Company believes that with this recent change effectuated by FINRA that it will eliminate confusion in the marketplace for existing and future stockholders.

ABOUT ORGANICELL REGENERATIVE MEDICINE, INC.

Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) is a clinical-stage biopharmaceutical company that harnesses the power of exosomes to develop innovative biological therapeutics for the treatment of degenerative diseases. The Company's proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Mari Mitrani, Chief Scientific Officer. To learn more, please visit https://organicell.com/.

FORWARD-LOOKING STATEMENTS

Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the "Securities Act"), the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as "will", "believes", "expects", "potential", or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally, and other known and unknown risks and uncertainties, including the risk factors discussed in the Company's periodic reports that are filed with the SEC and available on the SEC's website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release.

PRESS RELEASE

Media Contact:

Joshua Rodriguez[emailprotected](503) 464-6502

SOURCE Organicell Regenerative Medicine, Inc.

Home-Zeo

Go here to read the rest:
FINRA Approves Marketplace Name Change to Organicell Regenerative Medicine, Inc. and Trading Symbol Change To "OCEL" - PRNewswire